Elicio Therapeutics (NASDAQ: ELTX) grants RSUs and options to senior officer

Rhea-AI Filing Summary

Elicio Therapeutics granted equity awards to its Chief Strategy and Financial Officer, Preetam Shah, on February 2, 2026. He received 24,000 restricted stock units, each representing one share of common stock at no cost on grant, and 47,900 stock options to buy common shares at an exercise price of $8.10 per share.

The RSUs vest 25% on February 2, 2027, with the rest vesting in annual installments over the following three years, contingent on continued service. The options vest 25% on February 2, 2027, with the remainder vesting in monthly installments over three years thereafter, also subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Shah Preetam

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	47,900	$0.00	--
Grant/Award	Common Stock	24,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 47,900 shares (Direct); Common Stock — 24,000 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Preetam

(Last) (First) (Middle)

C/O ELICIO THERAPEUTICS, INC.

451 D STREET, 5TH FLOOR, SUITE 501

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elicio Therapeutics, Inc. [ ELTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		24,000(1)	A	$0(1)	24,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.1	02/02/2026		A		47,900		(2)	02/02/2036	Common Stock	47,900	$0	47,900	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer.

2. The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

Chief Strategy and Financial Officer

	/s/ Preetam Shah	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ELTX report for Preetam Shah on February 2, 2026?

Elicio Therapeutics reported that officer Preetam Shah received equity grants on February 2, 2026, including 24,000 restricted stock units and 47,900 stock options. Both awards were reported as acquired at no cost on the grant date, reflecting compensation rather than an open-market purchase.

How many Elicio Therapeutics (ELTX) RSUs did Preetam Shah receive?

Preetam Shah received 24,000 restricted stock units from Elicio Therapeutics. Each RSU represents the right to receive one share of ELTX common stock. The award is part of his compensation package and is subject to a multi‑year vesting schedule tied to continued service with the company.

What are the vesting terms for Preetam Shah’s ELTX restricted stock units?

The 24,000 ELTX restricted stock units vest 25% on February 2, 2027, marking the first anniversary of the grant. The remaining 75% vest in equal annual installments over the following three years, provided Shah continues serving Elicio Therapeutics through each applicable vesting date.

What stock options were granted to Preetam Shah by Elicio Therapeutics (ELTX)?

Elicio Therapeutics granted Shah 47,900 stock options with an exercise price of $8.10 per share. These options give him the right to buy ELTX common stock and were reported as acquired at no cost on grant, subject to a multi‑year service-based vesting schedule.

How do the ELTX stock options granted to Preetam Shah vest over time?

The 47,900 ELTX stock options vest 25% on February 2, 2027, one year after grant. The remaining 75% vest in monthly installments over the next three years, contingent on Shah’s continued service with Elicio Therapeutics through each monthly vesting date.

Is Preetam Shah’s ownership in ELTX recorded as direct or indirect?

The Form 4 records both the 24,000 restricted stock units and the 47,900 stock options as directly owned by Preetam Shah. There is no indication in the footnotes that these holdings are through a separate entity or that beneficial ownership is disclaimed.